iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with HR-positive, HER2-negative Early Breast Cancer By Ogkologos - November 14, 2024 779 0 Facebook Twitter Google+ Pinterest WhatsApp Final invasive disease-free survival results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR News digest – smoking ban, HPV and prostate cancer, genetic testing... July 18, 2020 Stem cell research: meet the scientist growing ‘mini guts’ in her... April 8, 2022 Thanks For Making This GivingTuesday Our Best One Yet! December 1, 2021 New Imaging Tool Could Predict Whether Hormone Therapy Will Work in... February 4, 2021 Load more HOT NEWS FDA Approves Tremelimumab in Combination with Durvalumab for Unresectable Hepatocellular Carcinoma Green Beret With Lung Cancer Surprised With Hundreds Of ‘Thank You’... Niraparib Maintenance Significantly Reduces the Risk of Disease Progression or Death... Healthy 33-Year-Old Nurse Learned She Had Cervical Cancer and Breast Cancer...
